Is cagrilintide approved?

No. As of mid-2026, cagrilintide is not an approved medicine in the European Union, the United States, or elsewhere. The CagriSema combination with semaglutide is under regulatory review, but review is not the same as approval, and cagrilintide on its own is not authorized for use.

Does cagrilintide work for weight loss?

In trials, to a degree, but with important caveats. A phase 2 study reported dose-dependent weight loss with cagrilintide alone, and the phase 3 REDEFINE 1 trial found clinically meaningful weight loss when it was combined with semaglutide. However, cagrilintide is not approved, and the long-term outcomes and safety of using it on its own are not established.

What are the side effects of cagrilintide?

Across clinical trials, the most common adverse events were gastrointestinal — nausea, constipation, and diarrhoea — along with injection-site reactions. Because cagrilintide is still investigational, its full long-term safety profile is not established, and research-market material is not a quality-assured or pharmacist-dispensed medicine.

What is CagriSema, and how does it relate to cagrilintide?

CagriSema is a once-weekly fixed combination of cagrilintide and the GLP-1 drug semaglutide, developed by Novo Nordisk for weight management. Most of cagrilintide's late-stage trial evidence comes from this combination rather than from cagrilintide alone. CagriSema is under regulatory review and is not yet approved.

How is cagrilintide different from semaglutide?

They act on different pathways: cagrilintide is an amylin analogue, while semaglutide is a GLP-1 receptor agonist. They are being studied together because their mechanisms are considered complementary for weight management. Semaglutide is already approved for several uses, whereas cagrilintide remains investigational.

Where can I buy Cagrilintide and compare vendors?

Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Metabolic

Buy Cagrilintide – Vendors, Prices, Testing and Evidence

Buy Cagrilintide

Also known as: AM833 · NNC0174-0833 · long-acting amylin analogue

Evidence grade B — Human, limitedRisk flag

Short answer

A long-acting amylin analogue studied for weight management, mostly in combination with semaglutide. Human trial data are substantial but it is not yet approved anywhere.

Where can you buy Cagrilintide?

Crystal Peptides. The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

What is known?

Cagrilintide is a long-acting synthetic analogue of amylin, a pancreatic hormone co-secreted with insulin that influences satiety and gastric emptying. It is being developed by Novo Nordisk for chronic weight management, primarily as a once-weekly combination with semaglutide known as CagriSema. It is an investigational drug, not an approved medicine.

What is not established?

A randomised phase 2 dose-finding trial (Lancet, 2021) reported dose-dependent weight reduction with cagrilintide monotherapy in people with overweight or obesity. The phase 3 REDEFINE 1 trial (NEJM, 2025) tested it combined with semaglutide and found clinically meaningful weight loss versus placebo. Cagrilintide alone is not approved, and long-term outcomes and safety of monotherapy are not established.

Safety

Across trials the most common adverse events were gastrointestinal (nausea, constipation, diarrhoea) and injection-site reactions. As an investigational product its full long-term safety profile is not established, and research-market material is not a quality-assured or pharmacist-dispensed medicine.

Regulatory status

Investigational; not an approved medicine in the EU or US as of mid-2026. Developed by Novo Nordisk; the fixed combination with semaglutide (CagriSema) is under regulatory review. Investigational product, not a general-use compound.

Not medical advice. This educational reference is not diagnosis, treatment, prescribing, dosing or emergency guidance. Consult a qualified professional before making health-related decisions.

Regulatory or safety concern: This substance may be unapproved for human use, affect the hormonal system, or be subject to regulator or anti-doping restrictions. Check the cited evidence and rules in your jurisdiction.

Vendor comparison

Buy Cagrilintide: compare vendors

The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

Vendor	Product	Documentation	Shipping	Checked	Action
Crystal Peptides Code PEPTIDES10 −10% · discount code details Sponsored	Cagrilintide research product	Vendor-supplied data COA stated as available Not independently documented	Europe See the localized country store	Jul 18, 2026	View at vendor

Crystal Peptides

Cagrilintide research product

Code PEPTIDES10 −10% · discount code details

What is it?

Research and evidence

Cagrilintide (also cataloged as AM833 or NNC0174-0833) is a long-acting synthetic analogue of amylin, a pancreatic hormone that is co-secreted with insulin and helps regulate satiety and the rate of gastric emptying. It is being developed by Novo Nordisk for chronic weight management, and it is studied most often not on its own but as a once-weekly fixed combination with the GLP-1 drug semaglutide, known as CagriSema. The single most important thing to understand about cagrilintide is that it is an investigational drug: it is not an approved medicine in the European Union, the United States, or elsewhere as of mid-2026.

The reason cagrilintide attracts serious attention is that, unlike many research-market peptides, it has a substantial human trial record. A randomized phase 2 dose-finding study (Lancet, 2021) reported dose-dependent weight reduction with cagrilintide used on its own in people with overweight or obesity, and the phase 3 REDEFINE 1 trial (NEJM, 2025) tested it combined with semaglutide and found clinically meaningful weight loss versus placebo. Its proposed mechanism — agonism of amylin and calcitonin receptors — sits on a well-characterized satiety-signalling pathway. Even so, cagrilintide on its own is not approved, and the long-term outcomes and safety of monotherapy are not established, which is why peptides.cx grades the evidence B rather than higher.

Across the trials, the most commonly reported adverse events were gastrointestinal — nausea, constipation, and diarrhoea — along with injection-site reactions. Because it remains an investigational product, its full long-term safety profile is not established, and material sold on the research market is not a quality-assured or pharmacist-dispensed medicine. The CagriSema combination is under regulatory review, but review is not approval, and nothing about that process changes cagrilintide's current status. This page is an educational reference summarizing what the science does and does not show; it is not medical advice, and it does not provide dosing, protocols, or sourcing guidance.

Evidence grade: B

Human evidence

Animal and preclinical evidence

Characterised in preclinical obesity models, where amylin-receptor agonism reduced food intake and body weight.

Proposed mechanisms

Agonism of amylin and calcitonin receptors, a well-characterised satiety-signalling pathway
Proposed slowing of gastric emptying and reduction of food intake
Discussed as complementary to GLP-1 receptor agonism when combined with semaglutide

Safety concerns and known side effects

Nausea
Constipation
Diarrhoea
Injection-site reactions

Regulatory status

Frequently asked questions about Cagrilintide

What is cagrilintide?: Cagrilintide (also known as AM833) is a long-acting synthetic analogue of amylin, a pancreatic hormone that influences satiety and gastric emptying. It is being developed by Novo Nordisk for chronic weight management, most often studied in a once-weekly combination with semaglutide called CagriSema. It is an investigational drug, not an approved medicine.
Is cagrilintide approved?: No. As of mid-2026, cagrilintide is not an approved medicine in the European Union, the United States, or elsewhere. The CagriSema combination with semaglutide is under regulatory review, but review is not the same as approval, and cagrilintide on its own is not authorized for use.
Does cagrilintide work for weight loss?: In trials, to a degree, but with important caveats. A phase 2 study reported dose-dependent weight loss with cagrilintide alone, and the phase 3 REDEFINE 1 trial found clinically meaningful weight loss when it was combined with semaglutide. However, cagrilintide is not approved, and the long-term outcomes and safety of using it on its own are not established.
What are the side effects of cagrilintide?: Across clinical trials, the most common adverse events were gastrointestinal — nausea, constipation, and diarrhoea — along with injection-site reactions. Because cagrilintide is still investigational, its full long-term safety profile is not established, and research-market material is not a quality-assured or pharmacist-dispensed medicine.
What is CagriSema, and how does it relate to cagrilintide?: CagriSema is a once-weekly fixed combination of cagrilintide and the GLP-1 drug semaglutide, developed by Novo Nordisk for weight management. Most of cagrilintide's late-stage trial evidence comes from this combination rather than from cagrilintide alone. CagriSema is under regulatory review and is not yet approved.
How is cagrilintide different from semaglutide?: They act on different pathways: cagrilintide is an amylin analogue, while semaglutide is a GLP-1 receptor agonist. They are being studied together because their mechanisms are considered complementary for weight management. Semaglutide is already approved for several uses, whereas cagrilintide remains investigational.
Where can I buy Cagrilintide and compare vendors?: Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Common discussion areas

CagriSema combination with semaglutideComparisons with GLP-1 drugsInvestigational / approval timelineGastrointestinal tolerability

Sources

Editorial review and transparency

Written by: peptides.cx Editorial Team
Scientific reviewer: No named medical reviewer is currently assigned
Last editorial review: July 18, 2026
Last vendor check: July 18, 2026
Review method: Source review, claim verification, vendor-data separation and regulatory-context review.
Commercial disclosure and conflicts: Vendor relationships do not determine evidence or safety ratings. No named reviewer conflict is recorded because no named reviewer is assigned.

Editorial policy →Evidence grade →Vendor methodology →

Related on peptides.cx

Library →Vendor quality checklist →Safety →Affiliate code: PEPTIDES10